Testing a new drug with chemotherapy for advanced bile duct and gallbladder cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called mitazalimab, which helps the immune system fight cancer, combined with standard chemotherapy (FOLFOX) for people whose bile duct or gallbladder cancer did not respond to or stopped responding to initial immunotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of bile duct or gallbladder cancer that is not removable by surgery, has spread, or came back after surgery.
- You must have already received a standard first-line treatment (chemotherapy plus an immunotherapy drug) and are now eligible for a different chemotherapy called FOLFOX.
- You need to have a tumor sample (archived or a new biopsy) available for testing.
- You must be able to perform daily activities with minimal help (ECOG 0 or 1).
- You should not have severe heart, kidney, or liver problems, and must not have certain infections like HIV or active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, for people with advanced bile duct or gallbladder cancer that has grown after previous treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This trial tests a new immunotherapy drug called envafolimab for people with advanced bile duct or gallbladder cancer. The goal is to see if it can help shrink tumors or slow the disease.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.